Degarelix for prostate cancer (Q37488225)

20 August 2017

1 reference

title

Degarelix for prostate cancer (English)

1 reference

20 August 2017

1 reference

Christian Doehn

1

1 reference

20 August 2017

Martin Sommerauer

series ordinal

2

1 reference

20 August 2017

Dieter Jocham

series ordinal

3

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 June 2009

1 reference

Expert Opinion on Investigational Drugs

20 August 2017

published in

1 reference

20 August 2017

volume

18

1 reference

20 August 2017

issue

6

1 reference

20 August 2017

page(s)

851-860

1 reference

20 August 2017

cites work

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1517%2F13543780902954713

Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902954713

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902954713

Survival in men with nonmetastatic prostate cancer treated with hormone therapy: a quantitative systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902954713

Guideline for the management of clinically localized prostate cancer: 2007 update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902954713

Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902954713

Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902954713

Hormonal therapy: historical perspective to future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902954713

Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902954713

Gonadotropin-releasing hormone agonists in the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902954713

Hypothalamic control of anterior pituitary function: a history

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902954713

Development of GnRH antagonists for prostate cancer: new approaches to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902954713

Molecular biology of the androgen receptor: from molecular understanding to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902954713

Highly potent antagonists of luteinizing hormone-releasing hormone free of edematogenic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902954713

GnRH antagonists: a new generation of long acting analogues incorporating p-ureido-phenylalanines at positions 5 and 6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902954713

Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902954713

Biodegradable microparticles for sustained release of a new GnRH antagonist--part I: Screening commercial PLGA and formulation technologies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902954713

Biodegradable PLGA microparticles for sustained release of a new GnRH antagonist: part II. In vivo performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902954713

The dosing solution influence on the pharmacokinetics of degarelix, a new GnRH antagonist, after s.c. administration to beagle dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902954713

Population pharmacokinetic modeling of a subcutaneous depot for GnRH antagonist degarelix

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902954713

Pharmacokinetic/pharmacodynamic modelling of GnRH antagonist degarelix: a comparison of the non-linear mixed-effects programs NONMEM and NLME.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902954713

'Vanishing' prostate cancer in radical prostatectomy specimens: incidence and long-term follow-up in 38 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902954713

A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902954713

Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker--results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902954713

STUDIES ON PROSTATIC CANCER

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902954713

Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902954713

Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902954713

Is the flare phenomenon clinically significant?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902954713

Survival following primary androgen deprivation therapy among men with localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902954713

The changing face of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902954713

Androgen deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902954713

Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902954713

Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902954713

Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902954713

Systematic review of early vs deferred hormonal treatment of locally advanced prostate cancer: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902954713

LHRH agonists in prostate cancer: frequency of treatment, serum testosterone measurement and castrate level: consensus opinion from a roundtable discussion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902954713

Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902954713

10.1517/13543780902954713

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference